Higaox

Quick links to important sections

Higaox

Method of action: Anti-Inflammatory

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Higaox

Property Description
Active ingredient Silibinin (Silybin A and Silybin B)
Form Capsules (Oral); Injectable solution (IV derivative)
Pharmacological class Hepatoprotective agent, Antihepatotoxic drug
Common purpose Supporting and protecting liver function
Origin Natural product (Milk thistle plant extract)

Higaox is a specific medicinal product whose identity is defined by its core active substance, Silibinin, and its classification as a specialized hepatoprotective agent designed to support and protect the liver. It represents a targeted therapeutic approach formulated for consistent delivery of the active component.


What is Higaox and Its Natural Origin?

Higaox is a preparation based on Silibinin, which is chemically defined as a flavonolignan derived from the seeds of the milk thistle plant (Silybum marianum). This compound is classified as a natural product. The active ingredient itself is a mixture of two closely related components, the diastereomers Silybin A and Silybin B. Silibinin is considered the most biologically active constituent of the milk thistle seed extract. As such, Silibinin is the key component providing the recognized liver-supporting benefits.


What Pharmacological Class Does Silibinin Belong To?

Silibinin is formally categorized as an antihepatotoxic drug and a hepatoprotective agent, signifying its primary function of safeguarding the liver. Higaox is positioned as a single-ingredient product commonly supplied in capsules for oral administration, typically utilized for adults requiring ongoing hepatic support, as observed in cases of chronic liver changes. The active component is recognized for its ability to stabilize liver cell membranes. While the oral capsule form is generally used for continuous support, specialized water-soluble salts of Silibinin are developed for use as an injectable solution when rapid, high-concentration delivery is essential in a professional clinical setting.


General Purpose: What Does Higaox Help the Liver Do?

The general purpose of Higaox is to maintain and support optimal liver function by protecting the structural integrity of liver cells. Its physiological action involves serving as a potent antioxidant, neutralizing harmful free radicals that cause stress and injury to tissues. Furthermore, it acts as a cellular shield, stabilizing the outer membranes of hepatocytes and promoting the liver's capacity for self-repair and regeneration. This comprehensive support helps preserve the function vital for detoxification and metabolic processes in individuals with existing liver burdens.

Regulatory References

  1. Milk Thistle (Silybum marianum) - NCBI Bookshelf

What side effects are possible with Higaox?

Possible Side Effects and Safety Information

The safety profile of Higaox is formally documented by governmental regulatory authorities, classifying risks and adverse reactions to inform prescribing and monitoring.

Adverse Reaction Scope

Adverse reactions are organized by System-Organ Class (e.g., Gastrointestinal Disorders, Nervous System Disorders) and typically categorized by frequency using regulatory conventions (e.g., common, uncommon, rare).

Classification Common Adult Adverse Reactions Common Pediatric Adverse Reactions
Most Common Insomnia, Nausea, Anxiety Headache, Insomnia

Serious Adverse Reactions (SAEs): Regulatory definitions categorize a Serious Adverse Event as an outcome that is life-threatening, results in death, requires hospitalization, causes significant disability, or is an important medical event that may jeopardize the patient.

Safety Warnings and Precautions: Official labeling highlights specific areas requiring caution or monitoring, including the risk of QT Interval Prolongation. Use of Higaox should be avoided with other drugs that increase the QT interval or in patients with existing risk factors for a prolonged QT interval. Monitoring of the QTc interval is required for patients with hepatic or renal impairment.

Safety Considerations for Specific Populations

Official labeling addresses the use of Higaox in Specific Populations, including considerations for pediatric patients (age 6 and older), and caution for use in individuals with hepatic impairment. The drug is formally Contraindicated in patients with known hypersensitivity to the drug or any component of the formulation, and in those with severe hepatic impairment.

Safety-Related Restrictions: Dosage adjustments or limits are formally defined for patients taking strong CYP2D6 inhibitors. Furthermore, Higaox may reduce the effectiveness of sensitive CYP3A4 substrates, including hormonal contraceptives.

Regulatory Safety Summary

Regulatory documents stipulate continuous post-marketing surveillance (pharmacovigilance) for prompt identification and reporting of risks. The required labeling provides a structured framework for understanding the potential risks and necessary cautions associated with the drug's use, particularly regarding cardiac monitoring and drug-drug interactions.

This structure ensures all officially documented risks, from common side effects to serious warnings, are clearly presented to guide the safe management of Higaox.

Overdose and Emergency Response

Higaox Overdose and When to Seek Help

Documented Overdose Profile

Official regulatory documentation states that no case of overdose has hitherto been reported for the active substance in Higaox. Consequently, the expected clinical presentation is considered an amplification of known undesirable effects, which primarily involve the Gastrointestinal system (e.g., mild symptoms like nausea, abdominal pain, or diarrhea) and the Immune system or Skin (e.g., hypersensitivity reactions like rash or urticaria). Due to the potential for severe, amplified reactions, overdose is viewed as a serious scenario that necessitates immediate professional medical intervention. There are no unique population-specific considerations documented in the official overdose sections.


Required Emergency Actions

Immediate medical help is required in the case of a suspected overdose or accidental ingestion. Official guidance mandates the following immediate actions:

  • Stop taking the medication.
  • Get medical help or contact a Poison Control Center right away.
  • Immediately go to the nearest hospital for timely treatment.

Overdose management is constrained by the fact that no specific antidote is known for the active substance. Treatment is therefore explicitly directed to be symptomatic and supportive. This lack of a specific reversal agent underscores the regulator-mandated requirement for urgent care.

Therapeutic Uses of Higaox

Higaox is commonly used in situations involving certain distressing symptoms across a range of conditions characterized by periods of heightened symptoms and involving episodic or fluctuating manifestations. The therapeutic domain is considered relevant in contexts marked by increased discomfort or tension, where supportive symptom management is appropriate. In this context, management for many chronic, persisting conditions often involves comprehensive strategies to manage symptoms across multiple body systems.

Higaox may assist with managing symptoms related to physical discomfort and symptoms that create noticeable physiological strain that interfere with routine activities. It is applied in clinical settings that involve acute or unstable symptom patterns, or in scenarios where additional management of discomfort is required. Higaox is relevant for easing symptom clusters that may become intense or disruptive. The product is commonly applied to help with scenarios involving supporting patients during episodes associated with acute physiological strain, systemic imbalance, and inflammatory or irritative states. This approach contributes to easing the overall symptom load during these periods, and may help patients cope more steadily with symptom fluctuations, supporting the patient during difficult episodes.

Quick Fact: Support for symptoms that interfere with daily functioning

As one patient-oriented benefit states, “Higaox supports general well-being during symptomatic phases.”

Regulatory References

  1. National Center for Biotechnology Information overview of multi-symptom disorders

Eligibility and Restrictions for Use

Official Eligibility Rules for Higaox

The eligibility for Higaox (Silibinin) is strictly defined by regulatory documents, which establish specific populations that are permitted, restricted, or prohibited from using the medicine.

Absolute Contraindications (Must Not Use)

Classification Population/Condition
Hypersensitivity Patients with a known allergy to Silibinin or any plant in the Asteraceae (Compositae) family (e.g., milk thistle).
Anatomical Condition Patients with documented obstruction of the bile duct (biliary tract).

Age and Developmental Status

Higaox is generally approved for use in adults (18 years and older). Regulatory authorities state that use is not recommended for children and adolescents under 18 years of age because safety and efficacy data for this age group are not established.

Restricted and Conditional Use

Classification Restriction/Limitation
Pregnancy/Lactation Use is not recommended or is contraindicated during both pregnancy and breastfeeding due to the absence of sufficient established human safety data.
Organ Function Patients with active liver disease must consult a qualified health professional before use. Restrictions may also apply to individuals with severe hepatic impairment or severe renal impairment.

What should I know about interactions with other medicines?

The official interaction profile for Higaox (Silibinin) is characterized by a lack of clinically significant interactions at established therapeutic doses, as determined by regulatory authorities. The product's interaction status is based on a formal review of both in vitro potential and human clinical data.

Formal Interaction Classifications

Classification Regulatory Status
Contraindicated Combinations None documented. Official prescribing information does not list any medicinal products that are formally prohibited for co-administration due to interaction risk.
Timing Rules or Restrictions None documented. There are no mandatory requirements for separating the administration of Higaox from any other medicine based on documented interactions.

Pharmacokinetic Interaction Potential

The active component, Silibinin, has demonstrated the potential in laboratory studies to interfere with certain drug-metabolizing enzymes and transporters, such as the Cytochrome P450 (CYP) enzymes (e.g., CYP3A4, CYP2C9) and the P-glycoprotein (P-gp) efflux transporter. The regulatory consensus, however, maintains that these findings are generally considered unlikely to be clinically significant in patients taking Higaox at therapeutic levels. Clinical human studies have not demonstrated a need for mandatory dose alterations or specific restrictions for co-administered medicines. The profile confirms that no specific drug is officially identified as having its plasma concentration significantly altered by Higaox, based on current regulatory documentation from health authorities.

Mechanism of Action

Stabilizing Cell Membranes and Organelles

The active component, Silibinin, physically interacts with the lipid bilayer of hepatocyte membranes and mitochondria to reinforce their structure. This physical action promotes cytoprotection by limiting the permeability of the cell to external toxins, which reduces acute structural damage and supports metabolic continuity within the cell.


Modulating Oxidative Stress and Inflammation

Silibinin acts as a free radical scavenger and functions as a modulator of intracellular signaling. It activates the Nrf2 pathway, increasing the production of antioxidant enzymes, while concurrently suppressing the NF-kappaB inflammatory pathway. This dual regulation modulates cellular redox potential and attenuates inflammatory signaling, influencing the severity of tissue stress.


Controlling Fibrosis and Influencing Regeneration

The mechanism involves interrupting the process of pathological tissue scarring by inhibiting the activation of Hepatic Stellate Cells (HSCs), primarily via the TGF-beta1 signaling pathway. Concurrently, the molecule stimulates RNA Polymerase I, accelerating protein synthesis necessary for cell repair. This contributes to modulating tissue remodeling and promoting hepatocyte repair and regeneration.

Dosage and Administration Information

Higaox is administered via two different routes depending on the clinical scenario. The product is primarily intended for long-term use as an oral capsule to provide continuous support, but is also available as an injectable solution for specialized short-term use.

Standard usage patterns follow the specific formulation. For ongoing, maintenance regimens, the standard oral dosage range is typically 420 mg to 600 mg of Silibinin equivalent per day. The total daily amount is typically administered in a divided regimen across two or three separate doses. The capsules should be taken with water and, as a rule, are used as part of a continuous support plan.

The intravenous (IV) form is reserved for use in acute, high-need episodes only. This specialized product requires dilution with an appropriate solution, such as 5% glucose, prior to administration. The IV regimen specifies high-dose protocols, such as 20 to 40 mg/kg per day, which must be delivered via slow, controlled infusion in a monitored setting. This short-term IV course is always followed by a rapid transition to the oral capsule once the acute phase is stabilized. Furthermore, dosing may require careful modification in patients exhibiting severe hepatic impairment.

Recent Clinical Evidence

Research evidence / Overview of studies for Higaox

This overview describes the scope and structure of the official research that has examined Silibinin, the active ingredient in Higaox. This summary focuses only on what type of studies exist, what they measured, and where scientific uncertainty remains. It does not provide clinical guidance or recommendations.


Evidence for Use in Chronic Liver Conditions: Alcoholic Liver Disease (ALD)

Research for Silibinin in conditions characterized by chronic liver changes includes evidence derived from Randomized Controlled Trials (RCTs) and Meta-analyses. Studies explored the measurements of outcomes in adult populations diagnosed with ALD. The main focus of research was monitoring specific outcomes, including liver function indicators such as ALT, AST, and GGT, as well as parameters related to blood fats (lipids).

While research describes observations regarding measurements of enzyme levels, findings were mixed across various reports. The evidence landscape for this condition also involves studies of a broader extract (Silymarin), which introduces variability and limits consistent conclusions specifically for the purified Silibinin found in Higaox. Some authoritative scientific reviews report that the overall clinical evidence is still insufficient or highly heterogeneous.


Evidence for Use in Fatty Liver Conditions: NAFLD and NASH

The use of Silibinin was evaluated in adults with Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH). Research has primarily consisted of Randomized Controlled Trials designed to monitor outcomes related to systemic or functional imbalance. Studies examined changes in specific liver enzyme measurements and metabolic markers, including blood lipids and fasting glucose.

Studies reported observations on the magnitude of change measured in these biomarkers over defined time intervals. Research highlights changes measured during the study period, but the findings were sometimes inconsistent, particularly concerning measurements of fat accumulation in the liver. Furthermore, evidence remains limited regarding the long-term changes observed in the progression of these conditions. Research notes that evidence quality varies across studies.


Evidence Gaps and Areas of Scientific Uncertainty

Several areas of limitation have been identified by scientific bodies. Findings were mixed across many trials, due to studies using different compound formulations, patient populations, and methodologies. Sample sizes were often modest, and follow-up durations were limited, meaning the data are still emerging regarding long-term results. Comparative evidence against other standard hepatoprotective approaches is lacking in many contexts. Research is ongoing to address these gaps.

Key Studies & References

  1. Effect of silymarin/silybin in children and adults with non alcoholic fatty liver disease: a systematic review and meta-analysis of randomized controlled trials
  2. Silibinin/Silymarin in the Treatment of Liver Diseases: A Brief Review

Frequently Asked Questions (FAQ)

Common questions about Higaox (FAQ)


Q: Does Higaox interact with commonly used over-the-counter pain relievers?

Official regulatory documents indicate that the potential for clinically significant drug interactions with Higaox is considered unlikely at established therapeutic doses. Regulatory information does not list any specific over-the-counter pain relievers as requiring mandatory restrictions or dose adjustments for co-administration.


Q: Can Higaox cause headaches or dizziness?

Adverse reaction reports indicate that headache is listed as a common side effect in pediatric patients. Dizziness is also reported in the safety profile as a possible side effect, though the frequency with which it occurs may not be consistently established across all patient groups.


Q: Does Higaox interact with herbal supplements like St. John's Wort?

Official prescribing information notes that the active ingredient has the potential in laboratory studies to interfere with certain drug-metabolizing enzymes in the liver. Since many herbal products, such as St. John's Wort, also interact with these same enzyme pathways, official sources describe this mechanism as one to be aware of when considering co-administration with other substances that affect these enzymes.


Q: Does Higaox have a specific time of day it works best?

Official regulatory guidelines direct that the total daily dosage be administered in a divided regimen across two or three separate doses. However, official information does not stipulate a specific time of day (such as morning or evening) for administration.


Q: Why do some people feel sleepy when they take Higaox?

The official side effects profile lists central nervous system (CNS) effects such as Insomnia (difficulty sleeping) and Anxiety as common adverse reactions. While the profile lists these effects, the occurrence of sleepiness or somnolence as a common adverse reaction is not explicitly listed in the official safety materials.


Q: Does Higaox interact with any common blood pressure medications?

Official documents indicate that clinically significant drug interactions are considered unlikely at established therapeutic doses. There is no requirement for mandatory dose alterations or specific restrictions for co-administered medicines, including those for blood pressure.


Q: Does the research evidence for Higaox cover diverse patient populations?

Regulatory documents indicate that research evidence for Higaox has been primarily examined in adult populations with specific chronic liver conditions. The reports acknowledge that study findings were described as variable, often due to differences in the patient populations or methods used in the research.


Q: Is it common to have stomach upset when first starting Higaox?

The official safety profiles list nausea as a common adverse reaction associated with the medicine. Reports from regulatory sources also include possible mild gut symptoms such as stomach irritation or diarrhea.


Q: Does Higaox have a 'Black Box Warning' or similar safety alert?

Official US regulatory labeling uses specific terms, such as Contraindication and serious Safety Warning, to highlight the most significant risks. Official warnings highlight specific serious risks, such as the potential for QT Interval Prolongation and restrictions for patients with severe hepatic impairment.


Q: Do studies suggest Higaox is generally well-tolerated?

The official side effect profile describes common adverse reactions as mild (e.g., nausea, insomnia). However, research reviews indicate that the overall clinical evidence is still described as variable or inconsistent across different studies.


Q: Can Higaox cause skin reactions or rashes?

Official regulatory documents report that allergic reactions are possible with Higaox. These reactions may include mild dermatological symptoms such as rashes, itching, or other skin reactions. The exact frequency of these events in the general population is not always known.


Q: What happens if I miss taking Higaox?

Standard patient instruction is to take the dose as soon as it is remembered, unless it is close to the time for the next scheduled dose. Standard patient instruction recommends not doubling the next scheduled dose to make up for the one that was missed.


Q: Are there any known issues with drinking alcohol while taking Higaox?

As the active ingredient is a hepatoprotective agent intended to support liver function, some official sources note that the medicine's supportive properties may be best realized when alcohol is avoided.


Q: Is Higaox affected by the foods I eat?

Official guidance often suggests taking the oral capsules with meals or shortly after eating. This is because taking it with food is described as a way to support the absorption of the active ingredient into the body.


Q: Does taking Higaox affect my ability to drive or operate machinery?

Official labeling contains specific warnings or cautions based on the risk profile. Given that common adverse reactions include insomnia and anxiety, it is important to consider that these effects may potentially impact the ability to drive or safely operate machinery.


Q: Is Higaox available as a generic version?

The core active ingredient in Higaox, Silibinin, is listed under many different international brand names and various formulations. This indicates that a number of preparations containing the same active component are available globally.


Q: Is Higaox used to prevent a condition or only to treat it?

The medicine is formally categorized as a hepatoprotective agent and is intended for supporting and protecting the liver. The specific regulatory indication, which defines whether its approved use is for treatment, support, or prevention, is detailed on the official product label.


Q: Why is Higaox sometimes taken with food?

Official guidance indicates that the primary reason for taking the oral capsules with food is to support the absorption of the active ingredient into the body. This practice is often described as a way to help maximize the amount of the drug that enters the bloodstream.

How should Higaox be stored and disposed of?

How to Store and Dispose of Higaox: Official Regulatory Guidelines

Storage Conditions

Higaox (Silibinin capsules) must be stored at a controlled room temperature, specifically below 25°C (77°F), to maintain its stability. The medicine must be protected from moisture and kept in a dry place. It is essential to not freeze or refrigerate the oral capsules. For safety and stability, the product must remain in its original container, which must be kept tightly closed.

Disposal and Child Safety

All unused or expired Higaox must be disposed of according to local regulations for pharmaceutical waste. Do not dispose of the medicine via wastewater (e.g., sink or toilet) or household trash unless directed otherwise by a local program. As with all medicines, Higaox must be stored out of the sight and reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Higaox found in:

A-Z Index: